PL2625199T3 - Sposoby leczenia łuszczycy z zastosowaniem antagonistów il-17 - Google Patents

Sposoby leczenia łuszczycy z zastosowaniem antagonistów il-17

Info

Publication number
PL2625199T3
PL2625199T3 PL11764764T PL11764764T PL2625199T3 PL 2625199 T3 PL2625199 T3 PL 2625199T3 PL 11764764 T PL11764764 T PL 11764764T PL 11764764 T PL11764764 T PL 11764764T PL 2625199 T3 PL2625199 T3 PL 2625199T3
Authority
PL
Poland
Prior art keywords
antagonists
methods
treating psoriasis
psoriasis
treating
Prior art date
Application number
PL11764764T
Other languages
English (en)
Inventor
Achim Guettner
Matthias Machacek
Charis Papavassilis
Oliver Sander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2625199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2625199T3 publication Critical patent/PL2625199T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PL11764764T 2010-10-08 2011-10-07 Sposoby leczenia łuszczycy z zastosowaniem antagonistów il-17 PL2625199T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists
EP11764764.4A EP2625199B1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (1)

Publication Number Publication Date
PL2625199T3 true PL2625199T3 (pl) 2018-04-30

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11764764T PL2625199T3 (pl) 2010-10-08 2011-10-07 Sposoby leczenia łuszczycy z zastosowaniem antagonistów il-17

Country Status (27)

Country Link
US (6) US9717791B2 (pl)
EP (4) EP3299390A1 (pl)
JP (2) JP5537740B2 (pl)
KR (3) KR20130110179A (pl)
CN (2) CN107029234A (pl)
AU (1) AU2011311482B2 (pl)
BR (1) BR112013008501A2 (pl)
CA (1) CA2813900C (pl)
CL (1) CL2013000930A1 (pl)
CY (1) CY1119942T1 (pl)
DK (1) DK2625199T3 (pl)
ES (1) ES2660770T3 (pl)
HK (1) HK1247932A1 (pl)
HR (1) HRP20180301T1 (pl)
HU (1) HUE038334T2 (pl)
IL (1) IL225310A (pl)
LT (1) LT2625199T (pl)
MA (1) MA34646B1 (pl)
MX (1) MX356279B (pl)
NO (1) NO2625199T3 (pl)
PL (1) PL2625199T3 (pl)
PT (1) PT2625199T (pl)
RU (2) RU2665954C1 (pl)
SG (1) SG188979A1 (pl)
SI (1) SI2625199T1 (pl)
TW (2) TWI564022B (pl)
WO (1) WO2012045848A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20121691A1 (es) 2010-01-15 2012-12-14 Kirin Amgen Inc Formulacion de anticuerpos y regimenes terapeuticos
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2015504430A (ja) * 2011-11-21 2015-02-12 ノバルティス アーゲー Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
EP2968486A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
EP4223312A1 (en) 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
CA2935046C (en) * 2013-12-27 2021-04-13 Osaka University Vaccine targeting il-17a
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
EP3126392B1 (en) * 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
MY186840A (en) * 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
KR20170045240A (ko) 2014-09-10 2017-04-26 노파르티스 아게 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AU2016226414B2 (en) 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
SG10202112586WA (en) * 2015-10-27 2021-12-30 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
CN109476733A (zh) * 2016-07-19 2019-03-15 诺华股份有限公司 使用il-17拮抗剂治疗新发斑块型银屑病的方法
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
WO2019040230A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company TREATMENT OF GENITAL PSORIASIS
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
WO2021018191A1 (zh) 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2621086A1 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007070750A1 (en) 2005-12-13 2007-06-21 Eli Lilly And Company Anti-il-17 antibodies
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
RU2341272C1 (ru) 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
PE20110345A1 (es) * 2008-09-29 2011-06-13 Roche Glycart Ag Anticuerpos contra la il17 humana

Also Published As

Publication number Publication date
TWI564022B (zh) 2017-01-01
CN103154031A (zh) 2013-06-12
HRP20180301T1 (hr) 2018-03-23
PT2625199T (pt) 2018-02-28
MX356279B (es) 2018-05-22
US20210113688A1 (en) 2021-04-22
SI2625199T1 (en) 2018-03-30
SG188979A1 (en) 2013-05-31
KR20150018595A (ko) 2015-02-23
MA34646B1 (fr) 2013-11-02
JP5537740B2 (ja) 2014-07-02
HK1247932A1 (zh) 2018-10-05
AU2011311482B2 (en) 2014-05-29
US20130202610A1 (en) 2013-08-08
IL225310A0 (en) 2013-06-27
AU2011311482A1 (en) 2013-04-04
IL225310A (en) 2016-10-31
NO2625199T3 (pl) 2018-04-21
US20170304439A1 (en) 2017-10-26
US20200171147A1 (en) 2020-06-04
JP2014114288A (ja) 2014-06-26
RU2591083C2 (ru) 2016-07-10
HUE038334T2 (hu) 2018-10-29
LT2625199T (lt) 2018-03-12
EP3792281A1 (en) 2021-03-17
ES2660770T3 (es) 2018-03-26
CL2013000930A1 (es) 2014-03-28
CA2813900A1 (en) 2012-04-12
RU2665954C1 (ru) 2018-09-05
TWI548419B (zh) 2016-09-11
EP4137514A1 (en) 2023-02-22
KR20130110179A (ko) 2013-10-08
KR20140097566A (ko) 2014-08-06
EP2625199A1 (en) 2013-08-14
BR112013008501A2 (pt) 2016-08-16
TW201630625A (zh) 2016-09-01
WO2012045848A1 (en) 2012-04-12
TW201216984A (en) 2012-05-01
RU2013120957A (ru) 2014-11-20
CN107029234A (zh) 2017-08-11
US11534490B2 (en) 2022-12-27
JP2013543501A (ja) 2013-12-05
CY1119942T1 (el) 2018-12-12
MX2013003916A (es) 2013-06-03
DK2625199T3 (en) 2018-02-26
US20230321231A1 (en) 2023-10-12
EP2625199B1 (en) 2017-11-22
US9717791B2 (en) 2017-08-01
US20210162044A1 (en) 2021-06-03
US10583190B2 (en) 2020-03-10
KR101620771B1 (ko) 2016-05-12
EP3299390A1 (en) 2018-03-28
CA2813900C (en) 2017-01-10

Similar Documents

Publication Publication Date Title
HK1247932A1 (zh) 利用il-17拮抗劑治療牛皮癬的方法
IL282625A (en) Use of the il-17 antibody to prepare a drug for the treatment of ankylosing spondylitis and rheumatoid arthritis
IL226401A0 (en) Methods for treating disorders related to @fgfBA
ZA201308859B (en) Quinazolines as therapeutic compounds and related methods of use
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
EP2773754A4 (en) Methods of Treatment
GB201110095D0 (en) Method of treatment
EP2717855A4 (en) PROCESSING METHODS
EP2628153A4 (en) METHOD FOR ESTABLISHING LINGUISTIC PROFILE
GB201018147D0 (en) Method of treatment
IL225623A0 (en) Psoriasis treatment methods
IL230433A0 (en) Pain management methods
IL256026B (en) Treatment methods
EP2701694A4 (en) METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
GB201003920D0 (en) Method of treatment
IL222844A0 (en) Biomarkers for the treatment of psoriasis
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2536421A4 (en) METHOD FOR THE TREATMENT OF DANDRUFFS
EP2709665A4 (en) TREATMENT OF PSORIASIS
GB0901456D0 (en) Treatment of psoriasis
IL200753A0 (en) Treatment of psoriasis
EP2585103A4 (en) METHOD OF TREATMENT
GB201018149D0 (en) Method of treatment
GB201107467D0 (en) Novel treatment of pain
GB201020015D0 (en) Method of treatment